Corona Remedies IPO is offer of ₹655.37 crore, entirely an Offer for Sale of about 0.62 crore equity shares. The issue opens for subscription from December 8, 2025 to December 10, 2025, with allotment expected on December 11 and listing on BSE and NSE on December 15, 2025. The company operates in the branded formulations space with strong return ratios and healthy margins, positioning the Corona Remedies IPO as a notable opportunity in the mid-sized pharma segment.
₹270
₹1062
₹
Expert Opinions
Corona Remedies IPO investors should note the company’s strong performance, with FY 2025 revenue rising 18% to ₹1,202.35 crore and PAT surging 65% to ₹149.43 crore, supported by EBITDA margin of 20.55%. The sector outlook is favorable, driven by sustained growth in chronic therapies, branded formulations, and increasing healthcare penetration in India. Valuation analysis of Corona Remedies IPO in 2025 shows a Return on Equity (ROE) of 27.50%, ROCE of 41.32%, Net Asset Value (NAV) of ₹99.14, low Debt/Equity of 0.10, and Price to Book Value around 10.71, indicating high capital efficiency but rich pricing versus some peers.
Growth prospects include capacity expansion, deeper doctor coverage, and portfolio scaling in women’s health and chronic segments. Key risk factors are high valuation, product concentration in top brands, and regulatory or pricing pressures. For investment horizon, long-term investors focused on quality pharma names may consider staggered exposure, while short-term traders must weigh listing gains potential against premium valuations.
Investor Considerations
Corona Remedies IPO investors should evaluate the company’s robust performance, with revenue growing 18% to ₹1,202.35 crore and profit after tax surging 65% to ₹149.43 crore in FY 2025, backed by strong EBITDA margins. The pharma sector outlook remains positive, driven by demand for chronic therapies and branded formulations amid rising healthcare access. Valuation analysis for Corona Remedies IPO in 2025 shows a Price to Book Value of 10.71, PAT Margin of 12.49%, and Debt/Equity ratio of 0.10, indicating premium pricing with excellent profitability and minimal leverage.
Growth prospects include expanding doctor networks, new product launches in women’s health, and capacity enhancements. Risks encompass product concentration, regulatory pricing pressures, and competition in generics. Long-term investors may benefit from steady pharma tailwinds, while short-term goals require caution on market volatility.
FAQs
Corona Remedies IPO Current GMP is ₹270.
Corona Remedies IPO Expected Returns is 25.42%.
Corona Remedies IPO estimated listing price is ₹1332.